证券代码：300878 证券简称：维康药业 公告编号：2025-014 浙江维康药业股份有限公司 关于拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、公司拟续聘的 2025 年度审计机构是天健会计师事务所（特殊普通合伙）。 其出具的公司《2024 年度审计报告》审计意见类型为保留意见。 2、本次不涉及变更会计师事务所。 3、公司审计委员会、董事会及监事会对本次拟续聘会计师事务所事项无异 议。 浙江维康药业股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开 第四届董事会第五次会议、第四届监事会第五次会议，审议通过了《关于拟续聘 会计师事务所的议案》，公司拟续聘天健会计师事务所（特殊普通合伙）（以下 简称"天健会计师事务所"）为公司 2025 年度审计机构，续聘事项尚需提交公 司股东大会审议。现将具体情况公告如下： 一、拟续聘会计师事务所事项的情况说明 天健会计师事务所具备证券及其衍生产品相关业务的审计从业资格，具有多 年为上市公司提供审计服务的经验与能力，合作多年以来为公司提供了高质量的 审计服务，其 ...

浙江维康药业股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召 开第四届董事会第五次会议、第四届监事会第五次会议，审议通过《关于 2024 年度计提资产减值准备的议案》，现将有关情况公告如下： 一、本次计提资产减值准备概况 一、计提减值准备的情况概述 浙江维康药业股份有限公司 关于 2024 年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300878 证券简称：维康药业 公告编号：2025-015 （一）计提信用减值准备和资产减值准备的原因 根据《企业会计准则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作（2023 年 12 月修订）》及公司会计政策等相关规定， 为更加真实、客观地反映公司截止 2024 年 12 月 31 日的资产状况和财务状况， 公司及下属子公司对 2024 年度各类应收款项等资产进行了全面清查，对可能 发生减值损失的资产计提资产减值准备。 （二）计提信用减值准备和资产减值准备的资产范围、总金额 公司及下属子公司对 2024 年末存在可能发生减值迹象的资 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-017 天健会计师事务所（特殊普通合伙）（以下简称"天健会计师事务所"）对浙 江维康药业股份有限公司（以下简称"公司"）2024 年度财务报表进行审计，出 具了保留意见的审计报告（天健审〔2025〕8836 号）。根据《公开发行证券的 公司信息披露编报规则第 14 号——非标准审计意见及其涉及事项的处理（2020 年修订）》和《深圳证券交易所创业板股票上市规则》等相关规定，公司董事会 对该非标准审计意见涉及事项作如下说明： 一、审计报告中保留意见所涉及事项 (一)资金占用及前期差错更正事项 如审计报告中"形成保留意见的基础"段所述，维康药业公司实际控制人过 去占用维康药业公司资金，导致前期财务报表多计长期资产、少计其他应收款。 2023 年度、2024 年度，维康药业公司已对上述事项进行了前期差错更正。实际 控制人分别于 2023 年 12 月、2024 年 3 月、2024 年 10 月和 2024 年 11 月归还占 用资金本金及利息。由于维康药业公司未能提供完整资料，我们无法就资金占用 金额及前期差错更正事项获取充分、适当的审计证据。 (二 ...

浙江维康药业股份有限公司 关于公司及子公司2025年度向银行申请授信额度及提供抵押或 质押担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开 第四届董事会第五次会议、第四届监事会第五次会议，审议通过了《关于公司及 子公司 2025 年度向银行申请授信额度及提供抵押或质押担保的议案》，本议案 尚需提交公司 2024 年度股东大会审议。现将具体情况公告如下： 一、申请综合授信额度事项概述 为满足公司及子公司 2025 年度日常生产经营及项目建设资金周转的需要， 公司及子公司 2025 年度拟向银行申请综合授信额度不超过人民币 15 亿元（含到 期后续授信），形式包括但不限于流动资金贷款、固定资产贷款、项目贷款、承 兑汇票、保函、开立信用证、票据贴现等综合业务。公司及子公司办理融资业务 时，可以以公司及子公司自有资产进行抵押担保或质押担保。 前述授信额度以相关金融机构实际审批的最终授信额度为准，具体融资金额 视公司实际经营情况需求决定，无需再逐笔形成决议；在综合授信额度内，公 ...

浙江维康药业股份有限公司 2024年度财务决算报告 浙江维康药业股份有限公司 2024 年度财务决算报告 一、2024年度财务报表审计情况 2024年度财务报表经天健会计师事务所（特殊普通合伙）审计，出具了保留 意见的审计报告（天健审〔2025〕8836号），天健会计师事务所认为，除"形成 保留意见的基础"部分所述事项可能产生的影响外，后附的财务报表在所有重大 方面按照企业会计准则的规定编制，公允反映了维康药业公司2024年12月31日的 合并及母公司财务状况，以及2024年度的合并及母公司经营成果和现金流量。 二、经营利润情况 单位：人民币元 | 项 目 | 2024年度 | 2023年度 | 增减幅度 | 大额变动原因说明 | | --- | --- | --- | --- | --- | | 营业总收入 | 351,198,567.67 | 519,621,071.15 | -32.41% | 主要系本期减少合并范围所致 | | 营业成本 | 217,105,289.06 | 257,094,058.81 | -15.55% | | | 税金及附加 | 11,711,547.79 | 2,795,552 ...

浙江维康药业股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开 了第四届董事会第五次会议，会议审议通过了《关于提请召开公司 2024 年度股东 大会的议案》，同意于 2025 年 5 月 20 日召开公司 2024 年度股东大会。现将本 次股东大会的相关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年度股东大会 2、会议召集人：公司董事会。 证券代码：300878 证券简称：维康药业 公告编号：2025-020 3、会议召开的合法性、合规性：公司第四届董事会第五次会议审议通过了《关 于提请召开公司 2024 年度股东大会的议案》。本次股东大会的召集、召开所履行 的程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》等的有 关规定。 4、会议召开日期和时间： （1）现场会议召开：2025 年 5 月 20 日（星期二）下午 14:00。 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的具体时 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-009 浙江维康药业股份有限公司 第四次监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江维康药业股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日以电 子邮件、专人送达或电话方式发出第四次监事会第五次会议通知，会议于 2025 年 4 月 27 日在浙江省丽水经济开发区遂松路 2 号研发大楼二楼会议室以现场方 式召开，应参加表决的监事 3 人，实际参加表决的监事 3 人，会议由公司监事会 主席叶志学主持。本次会议的召集、召开和表决程序符合有关法律、法规、部门 规章、规范性文件和《公司章程》的规定，会议形成的决议合法有效。 二、监事会会议审议情况 （一）审议通过《关于公司 2024 年度监事会工作报告的议案》 公司监事会审议通过了《2024 年度监事会工作报告》，具体内容详见公司 同日在巨潮资讯网（http://www.cninfo.com.cn）披露的《公司 2024 年度监事会工 作报告》。 表决结果：3 票同意，0 票反对， ...

证券代码：300878 证券简称：维康药业 公告编号：2025-008 二、董事会会议审议情况 （一）审议通过《关于公司 2024 年度总经理工作报告的议案》 与会董事认真听取了总经理刘洋先生所作的《2024 年度总经理工作报告》， 董事会认为 2024 年度公司经营管理层有效地执行了董事会和股东大会的各项决 议，该报告客观、真实地反映了经营管理层 2024 年度的主要工作。 表决结果：同意：7 票；反对：0 票；弃权：0 票。 （二）审议通过《关于公司 2024 年度董事会工作报告的议案》 浙江维康药业股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江维康药业股份有限公司（以下简称"公司"）第四届董事会第五次会议 通知于 2025 年 4 月 17 日以电子邮件、专人送达或电话方式送达全体董事，本次 会议于 2025 年 4 月 27 日在浙江省丽水经济开发区遂松路 2 号二楼会议室以现场 结合通讯方式召开。本次会议由董事长刘洋先生主持，公司应出席董事 7 人，实 际出席董事 7 人。本 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-016 | 项 目 | 调整前金额 | 调整金额 | 调整后金额 | | --- | --- | --- | --- | | 其他应收款 | 11,554,269.55 | 17,544,475.55 | 29,098,745.10 | | 其他流动资产 | 23,927,015.34 | -564,510.96 | 23,362,504.38 | | 固定资产 | 529,833,584.44 | 29,610,251.59 | 559,443,836.03 | | 在建工程 | 301,907,569.27 | -31,475,373.90 | 270,432,195.37 | | 资产总计 | 2,046,636,530.88 | 15,114,842.28 | 2,061,751,373.16 | | 应交税费 | 5,437,966.56 | 14,321,505.02 | 19,759,471.58 | | 负债合计 | 639,227,731.24 | 14,321,505.02 | 653,549,236.26 | | 盈余公积 ...

Financial Performance - The company reported a significant decline in performance, primarily due to the transfer of its wholly-owned subsidiaries, resulting in a non-recurring investment income of RMB 88.25 million, while also recognizing fixed asset impairment of RMB 76.20 million[3]. - Product sales revenue and gross margin decreased due to a drop in product prices and underperformance in sales and management[4]. - The company's operating revenue for 2024 was ¥351,198,567.67, a decrease of 32.41% compared to ¥519,621,071.15 in 2023[21]. - The net loss attributable to shareholders for 2024 was ¥-147,426,253.43, representing a significant increase of 1,546.42% from a loss of ¥-8,038,557.83 in 2023[21]. - The net cash flow from operating activities for 2024 was ¥-27,173,007.35, a decline of 146.62% from ¥58,289,136.41 in 2023[21]. - The total assets at the end of 2024 were ¥1,652,323,039.5, down 19.86% from ¥2,046,636,530.88 at the end of 2023[21]. - The net assets attributable to shareholders decreased by 16.75% to ¥1,157,666,559.7 at the end of 2024 from ¥1,389,807,852.57 at the end of 2023[21]. - The company reported a basic and diluted earnings per share of ¥-1.03 for 2024, a decrease of 1,616.67% from ¥-0.06 in 2023[21]. - The weighted average return on equity for 2024 was -11.75%, compared to -0.58% in 2023[21]. - The company reported a net profit attributable to shareholders of -¥191,521,798.32 in Q4, highlighting substantial losses in the last quarter[28]. Investment and R&D - The company plans to enhance its profitability by advancing core R&D projects, including innovative traditional Chinese medicine products and improved formulations, with a focus on market-ready short-term projects[6]. - The company emphasizes R&D investment and talent acquisition, establishing multiple research platforms to enhance its core competitiveness in the pharmaceutical field[40]. - The company is currently advancing several key projects, including the "Bone Spur Capsule," which is under review by the National Pharmacopoeia Committee[52]. - The "Yinhuang Diban" is in the clinical trial phase, having completed Phase II trials and currently in communication for Phase III trials[52]. - The company is conducting research on multiple traditional Chinese medicine formulations, including "Jichuan Decoction" and "Wenjing Decoction," which are in various stages of development[52]. - The company holds 37 drug approval numbers, with key products like Yinhuang Diban and Luohongmycin Soft Capsules having invention patents and core technologies[56]. - The company has established multiple research platforms, including provincial high-tech enterprise R&D centers and has received various provincial science and technology awards[56]. - The company plans to submit applications for several new traditional Chinese medicine products, enhancing its product line and potential revenue streams[80]. Market Strategy and Expansion - Efforts will be made to include more core products in the national medical insurance directory, which is expected to boost demand and market expansion[7]. - The company aims to increase production capacity for existing products and new product commercialization through investments in modern facilities[7]. - A nationwide marketing network has been established, with plans to further enhance its coverage and the professionalism of the sales team to support sustainable growth[7]. - The company is currently enhancing its research plans based on prior communications with CDE regarding the Silver Yellow Inhalation Solution[56]. - The company aims to strengthen the development of traditional Chinese medicine in response to national policies promoting healthcare and innovation in the pharmaceutical industry[36]. - The company is focused on maintaining the rights and interests of all shareholders through diligent oversight[166]. - The company plans to continue expanding its market presence and product development in the pharmaceutical sector[98]. Human Resources and Management - The company will strengthen human resource management and talent acquisition to support its rapid development and maintain a stable workforce[9]. - The management team has extensive experience in the pharmaceutical industry, contributing to effective market development and product quality control[60]. - The company has established an independent human resources department with a complete personnel management system[134]. - The company has a well-structured internal management organization, including a shareholders' meeting, board of directors, and supervisory board, ensuring independent operational authority[136]. - The company has a total of 650 employees, including 232 production personnel, 252 sales personnel, 87 technical personnel, 22 financial personnel, and 57 administrative personnel[172]. - The company emphasizes talent cultivation and has developed a comprehensive training system to enhance employee skills and meet the company's development needs[175]. Financial Management and Compliance - The company corrected prior financial statements due to a misappropriation of funds totaling ¥157,300,000, which included ¥54,000,500 of raised funds[22]. - The company plans to continue monitoring the use of raised funds and has transferred ¥54,000,500 back to the designated account[22]. - The company has a well-developed new drug research and development system, emphasizing market research and strict control at all stages, while increasing investment in R&D and talent acquisition to mitigate product development risks[117]. - The company has established a comprehensive quality management system based on drug quality risk assessment to ensure compliance with safety, efficacy, and quality control requirements throughout the production process[116]. - The company is actively monitoring changes in national pharmaceutical policies to proactively develop response measures[113]. - The company has been under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws[184]. - The company emphasizes compliance with laws and regulations, ensuring accurate and timely information disclosure to enhance operational transparency[188]. Shareholder and Governance - The board approved a profit distribution plan, proposing a cash dividend of RMB 1.4 per 10 shares, with no bonus shares issued[9]. - The company announced a change in leadership with Liu Yang being elected as Chairman and General Manager effective May 20, 2024[142]. - The company has a complete governance structure with independent directors and a supervisory board[141]. - The company has committed to not engage in direct or indirect competition with its own subsidiaries to protect its interests[194]. - The company will avoid similar investment projects to prevent competition with its own interests[194]. - The company has a strategy in place to address any potential misleading information in its public offering documents[200]. - The company is committed to establishing an investor compensation fund to address potential losses[200]. Operational Challenges - The company is facing challenges due to declining product prices and management performance, leading to adjustments in production plans[72]. - The company has reported a total of 5.5 million yuan in unused raised funds that have been idle for over two years[95]. - The investment in the pharmaceutical health industry park project has not met expected returns primarily due to lower-than-expected sales during the period[98]. - The company is currently advancing core R&D projects, including innovative traditional Chinese medicine products, with significant investment in research and development[105]. - The company faces policy risks related to the ongoing reforms in the medical and pharmaceutical sectors, which may impact its operations if not addressed timely[112].